Treatment with immune checkpoint inhibitors has been highly successful in a subset of tumor types, 27 particularly those with increased levels of immune infiltrate. However, the mechanism and the immune 28 cell subsets critical for successful clinical responses are not fully understood. This study demonstrates that 29 the chemokines CXCL9/10 are indispensable for robust responses to immune checkpoint inhibitors (anti-30 PD-1 and anti-CTLA-4) and, in particular, that CXCL9/10-secreting macrophages are critical for their 31 therapeutic efficacy. Moreover, we identified a novel transcriptional signature in macrophages that was 32 associated with positive patient responses to immune checkpoint inhibitors that was lacking in non-33 responding patients. This is of significant interest to the field, challenging the paradigm that macrophages 34 are pro-tumoral and detrimental to anti-tumor immune responses through immunosuppressive 35 mechanisms, including expression of PD-L1. These findings indicate that the intratumoral macrophage 36 phenotype is a key feature in determining responses to immune checkpoint inhibitors that can be exploited 37 either diagnostically or therapeutically.
was biopsied and the overall clinical response. The latter was used in classifying a case as a responder or 220 non-responder. Two cases were classified as treatment resistance, as they develop progressive disease after 221 an initial brief response. These cases were excluded to provide more distinct biology for comparison of 222 responders and non-responders. A gene signature was created from differential expression results by 223 selecting genes with an adjusted p value < 0.05 and log2 fold change > 2. The per cell signature score was 224 calculated by the sum of the expression of upregulated signature genes minus the expression of 225 downregulated signature genes, using scaled data in Seurat. 226 Single cell mRNASeq from the CT26 melanoma syngeneic model was also analysed in a similar fashion 227 to the above (35) . As this data is unique molecular identifier based, the sctransform normalization and 228 variance stabilization method was used.
229
Data Availability 230 nanoString data generated in this study is included as a supplementary file. 231 METABRIC processed gene expression data is available at www.cbioportal.org, and clinical data is 232 available as supplementary table 1 in Rueda et al. (36) . 233 TCGA melanoma gene expression data is available at www.cbioportal.org under the TCGA pan-cancer 234 atlas 2018 dataset, and curated survival data was obtained from Table S1 in Liu et al. (37) . and secondary antibodies conjugated with HRP. X-ray film was used to detect chemiluminescence.
260

CRISPR knockout cell line generation 261
To generate knockout cell lines, 37 pmoles sgRNA (Synthego) and 270 pmoles recombinant Cas9 (IDT) 262 were incubated together for 10 minutes at room temperature. sgRNA/Cas9 RNPs were then electroporated 263 into AT-3ova cells (3 x 10 5 ) using a Lonza SG Cell line kit and 4D-Nucleofector. 
Results
273
Intratumoral CXCL9 and CXCL10 expression is increased following immune checkpoint blockade 274 To investigate the chemokines required for effective therapeutic responses following immune checkpoint 275 blockade we utilized the AT-3ova model of triple negative breast cancer, which we have previously shown 276 to be responsive to dual PD-1/CTLA-4 blockade (19). As expected, when mice bearing AT-3ova tumors 277 were treated with anti-PD-1 and anti-CTLA-4 at day 14 post tumor inoculation, robust anti-tumor immune 278 responses were observed (Figure 1A, B ), whilst single agent treatment with either anti-PD-1 or anti- Figure 1A) . Since treatment of tumors 280 with anti-PD-1/anti-CTLA-4 is known to be associated with an increase in tumor-infiltrating lymphocytes 281 (19, 38), we investigated the chemokines that were upregulated in this context by performing gene 282 expression analysis on tumor samples obtained from mice treated with 2A3 isotype control or anti-PD-1 283 and anti-CTLA-4. This analysis revealed significant upregulation of numerous cytokines and chemokines 284 associated with T cell infiltration with CXCL9 (p = 0.001) and CXCL10 (p = 0.0001) being two of the 285 most significantly upregulated and abundant chemokines following dual immune checkpoint blockade 286 ( Figure 1C) . Similarly, CXCR3, the receptor for CXCL9/CXCL10, was also significantly upregulated in 287 tumors treated with anti-PD-1/anti-CTLA-4 (Supplementary Figure 1B) . Analysis of tumor supernatants 288 confirmed that several chemokines including CCL5, CCL22, CCL17, CXCL9 and CXCL10 were 289 significantly upregulated at the protein level following dual blockade of PD-1 and CTLA-4 ( Figure 1D ) 290 whereas blockade of either PD-1 or CTLA-4 alone resulted in modest increases in chemokine production 291 (Supplementary Figure 1C) . 292 We next analyzed the relevance of these chemokines in the context of melanoma patients treated with 293 either anti-PD-1 alone (Nivolumab or Pembrolizumab) or dual anti-PD-1/anti-CTLA-4 (ipilimumab) Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 15 therapy as previously described (23). Strikingly, the expression of CXCL9, CXCL10 and CXCL11 was 295 significantly higher in tumors isolated from responders at baseline ( Figure 1E ) and on therapy ( Figure   296 1F). Furthermore high expression of CXCL9 and CXCL10, in particular, was associated with improved 297 patient survival and increased numbers of intratumoral CD8 + T cells in these patients treated with immune 298 checkpoint blockade (Figure 1G-H) . Analysis of a separate cohort of melanoma patients treated 299 exclusively with Nivolumab single agent therapy revealed that CXCL9, CXCL10 and CCL5 were also 300 amongst the most highly upregulated genes in this cohort ( Supplementary Figure 2A) (27) . Moreover, 301 analysis of gene expression data from the IMvigor 210 trial indicated that the expression of CXCL9 (p= 302 0.0023), CXCL10 (p = 0.0074) and CXCL11 (P=0.029) were significant prognostic indicators in 303 metastatic urothelial carcinoma patients treated with atezolizumab, were expressed to a greater extent in To investigate the role of CXCL9 and CXCL10 in the therapeutic effect mediated by dual PD-1/CTLA-4 321 blockade, we first utilized a blocking monoclonal antibody for the CXCR3 receptor (Figure 2A) . Figure 2) , we further assessed the importance of CXCR3 330 in a model that was sensitive to PD-1 inhibition alone. To this end, we treated less established AT-3ova 331 tumors (Day 7 post inoculation) using anti-PD-1 alone, which also resulted in significant therapeutic 332 effects that were CXCR3 dependent ( Supplementary Figure 2E) . Taken together, these data demonstrate 333 the critical importance for the CXCR3/CXCR3 ligand axis for the therapeutic efficacy of anti-PD1/CTLA-334 4 therapy, and next sought to investigate the underlying mechanism. 335 We have previously shown that dual PD-1/CTLA-4 blockade significantly enhances both CD8 + and CD4 +
279
CTLA-4 resulted in limited anti-tumor activity (Supplementary
336
T cell effector functions in this model and that the therapeutic efficacy of this combination therapy is 337 dependent on both CD8 + and CD4 + foxp3cells (19). We therefore investigated the effect of CXCR3 (Figure 3G, Supplementary Figure 4C ). We next sought to identify whether the importance of CXCR3 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on October 21, 2019; DOI: 10.1158/1078-0432.CCR-19-1868 this we repeated our therapeutic studies in the context of S1PR blockade, using FTY720. Treatment of 362 mice with FTY720 significantly reduced the therapeutic efficacy of dual PD-1 and CTLA-4 blockade, to 363 a similar extent as anti-CXCR3 ( Figure 3H) . Moreover, blockade of CXCR3 did not affect the capacity 364 of OT-I T cells to produce cytokines when cocultured with tumor cells in vitro (Supplementary Figure   365 4D). Taken together, this data suggests that CXCR3-mediated enhancement of T cell cytokine production 366 in vivo is associated with enhanced migration of T cells to the tumor site which creates a more favorable 367 environment for T cell activation.
368
CXCR3 blockade affects the priming of CD8 + T cells within the tumor draining lymph node 369
Given that we have previously shown that the therapeutic effects of anti-PD-1/anti-CTLA-4 are dependent 370 on both CD4 + foxp3and CD8 + T cells and are associated with activation of these cells in the tumor draining 371 lymph nodes (DLNs) (19), we further investigated the phenotype of these cells in the DLNs in the context 372 of CXCR3 blockade. To investigate a potential role for CXCL9/CXCL10: CXCR3 interactions we first 373 evaluated the expression of these genes in cells isolated from DLNs of tumor bearing mice following PD- Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on October 21, 2019; DOI: 10.1158/1078-0432.CCR-19-1868 that dual PD-1/CTLA-4 blockade not only induces CXCR3-dependent migration of CD8 + T cells into the 385 tumor site but also that CXCR3 ligands modulate the activation of both CD8 + and CD4 + foxp3cells both 386 at the tumor site and within draining lymph nodes.
387
Intratumoral CXCL9 is predominantly secreted from macrophages following immune checkpoint 388 blockade 389 We next assessed the mechanism and cell types that were responsible for the generation of CXCR3 ligands 390 following immune checkpoint blockade. One possibility was that the production of CXCL9 and CXCL10 391 was mediated by tumor cells, since AT-3ova cells produced CXCL9 and CXCL10 following stimulation 392 with IFNγ and TNFα in vitro (Supplementary Figure 5A-B) . To assess the importance of tumor-derived 393 CXCL9/CXCL10 for the therapeutic effect of dual PD-1/CTLA-4 blockade, we generated AT-3ova cells 394 that did not express CXCL9 or CXCL10 using CRISPR-Cas9 mediated deletion of these genes. The 395 resulting cells produced negligible amounts of CXCL9/10 in vitro following dual TNFα and IFNγ 396 stimulation (Supplementary Figure 5C ). However, loss of CXCL9 and CXCL10 production by AT-3ova 397 tumor cells did not significantly affect their responsiveness to dual PD-1/CTLA-4 blockade ( Figure 5A ) 398 nor the level of CXCL9 within the tumor microenvironment following therapy ( Figure 5B ). This data 399 suggested that host cells were the major source of CXCL9 in the context of combination therapy which 400 was critical for the therapeutic effect. Accordingly, we assessed the cell types responsible for the 401 production of CXCL9 and CXCL10 in tumors of mice undergoing immune checkpoint therapy. Following Figure 6D ). Therefore, although CXCL9 production was increased in CD103 + cDC1s 410 (CD11c + CD103 + CD11b -) and tumor/stromal cells (CD45 -) following dual PD-1/CTLA-4 blockade Figure 6A) . 426 Production of CXCL9 and CXCL10 is IFN dependent 427 Given the known key role of IFNγ and TNFα in modulating CXCL9/10 expression in alternative contexts 428 (13, 42), we next assessed their importance in driving chemokine expression in vivo in the context of 429 immune checkpoint blockade. We found that IFNγ and TNFα levels were significantly enhanced in the high amounts of CXCL9 which could not be further enhanced by IFN, suggesting that this IFN pathway 444 was already activated in vivo. Notably, these effects were also observed in BATF3 -/mice, confirming that 445 these effects were independent of CD103 + DCs (Figure 6E ). However, we did observe that the overall 446 levels of CXCL9 production by macrophages were lower in BATF3 -/mice, suggesting that CD103 + DCs 447 indirectly contributed to the production of CXCL9 by these cells. Taken together, these data demonstrated 448 that Mo/Mac cells are the major source of tumor derived CXCL9 and CXCL10 after dual PD-1/CTLA-4 449 blockade and that this expression is driven by IFNγ that is induced following combination therapy. To investigate the requirement for macrophages for CXCL9/10 production following dual PD-1/CTLA-4 453 blockade, we depleted these cells using an anti-F4/80 antibody (Supplementary Figure 6H) which 454 resulted in a complete abrogation of the therapeutic efficacy of dual PD-1/CTLA-4 blockade ( Figure 7A ). 455 Depletion of macrophages also attenuated the increased production of CXCL9 ( Figure 7B ) and infiltration 456 of CD8 + and CD4 + foxp3cells within tumors following dual PD-1/CTLA-4 blockade (Figure 7C) . 457 Similarly, IFNγ neutralization also attenuated increased infiltration of CD8 + and CD4 + foxp3cells, 458 highlighting the link between IFNγ, macrophages and CXCL9 production. To investigate the clinical 459 significance of macrophage derived CXCR3 ligands (CXCL9/CXCL10/CXCL11) we next sought to 460 determine the source of these chemokines in human tumors and their prognostic significance.
461
Analysis of single cell RNA-seq datasets in melanoma (29), lung carcinoma (32) and head and neck cancer 462 cohorts (31) revealed that macrophages were the predominant cell type responsible for the production of populations were defined but CXCL9-11 were more highly expressed by CD68 expressing macrophages 466 than dendritic cells, including the CLEC9A + cDC1 population (Figure 7E) . This was consistent with all 467 human datasets analyzed where CXCL9-11 production was also detected in other immune cell populations 468 such as dendritic cells, but consistently to a lesser extent than macrophages (Figure 7D , Supplementary 469 Figure 7A-B) . Utilizing the melanoma dataset of Sade-Feldman et al., derived from single cell RNA-seq 470 analysis before and after immune checkpoint blockade, we were able to investigate the expression of these 471 chemokines in the context of immunotherapy (29). Differential gene expression analysis of macrophages 472 in responders and non-responders revealed that CXCR3 ligands, and in particular CXCL10 and CXCL11, 473 were more abundantly expressed in macrophages from responding patients (Figure 7F-G CXCL10 and CXCL11 which was more abundant in macrophages derived from patients that responded to 476 immune checkpoint blockade (Figure 7H, Supplementary Figure 7C) . Taken together, the data obtained 477 from these patient samples strongly supports our preclinical observation that macrophages are a major 478 source of CXCR3 ligands and are associated with responses to immune checkpoint blockade. (56). However, whilst CCL5 can potentially enhance anti-tumor immunity through the recruitment of 508 CCR5 + T cells and NK cells, pro-tumoral roles of CCL5 have also been reported (57, 58). Therefore 509 strategies to enhance CXCL9/10/11 production may be more favourable to those designed to enhance 510 CCL5 expression.
511
Our data indicating the importance of CXCL9/10/11: CXCR3 interactions for the efficacy of immune 512 checkpoint blockade in vivo was supported by transcriptome analysis of patients treated with either 513 atezolizumab (anti-PD-L1) or nivolumab (anti-PD-1), or a combination of ipilimumab and a PD-1 514 blocking antibody. In all cases, CXCL9/10/11 production was highly correlated with improved patient 515 survival and their production was associated with an IFNγ gene signature. Given that single cell RNA-seq 516 analysis revealed that CXCR3 is highly expressed on CD8 + and CD4 + tumor-infiltrating lymphocytes in 517 triple negative breast cancer (59), it is highly likely that local production of CXCL9/10 can modulate T 518 cell recruitment and activation in human cancers. Interestingly, a similar observation has been reported in 519 a study of 45 melanoma patients treated with ipilimumab where the increased expression of IFNγ 520 dependent genes including CXCL9-11 was observed in patients undergoing a clinical response (60). Our 521 analysis supports that these chemokines are also increased following anti-PD-1, that they are crucial for 522 therapeutic activity and correlate with patient prognosis. Therefore strategies to enhance the expression 523 and/or activity of CXCL9/10 may be expected to enhance the therapeutic efficacy of immune checkpoint (61, 62) . Similarly, the localized application of a COX-2 inhibitor was shown to enhance 527 therapeutic responses to anti-PD-1, associated with an increase in expression of CXCL9 and CXCL10 (63) 528 and epigenetic modulators (EZH2i and DNMT1i) were shown to enhance anti-tumor immune responses 529 associated with increased expression of CXCL9 and CXCL10 (64). However, given the broad non-specific 530 nature of these inhibitors, it is clear that more specific therapeutics to modulate the CXCL9/CXCL10 531 chemokines would be of significant interest.
532
Having established that CXCR3 was crucial to the anti-tumor efficacy of dual PD-1/CTLA-4 blockade we 533 next investigated the underlying mechanisms. We observed that CXCR3 blockade reduced CD8 + T cell 534 infiltrate into tumors following dual PD-1/CTLA-4 blockade whilst the numbers of other immune cell 535 populations such as CD4 + Tregs and NK cells were not affected. This was somewhat surprising given that 536 these cells express CXCR3 and expression of CXCL10 was shown to promote NK cell infiltration into the 537 NK sensitive RMA-S cell line (65). However, this data may either reflect a higher dependency of CD8 + T 538 cells on CXCR3 for their migration into the tumor site following immune checkpoint blockade than other 539 immune cell subtypes and/or our use of a T cell sensitive model where NK cells are unlikely to play a 540 major role in the control of tumor growth. This hypothesis is consistent with the fact that CXCR3 541 expression was increased following T cell activation by dual PD-1/CTLA-4 blockade. We did not 542 investigate the role of CXCL9 and CXCL10 in recruiting other immune cell types, including myeloid cells.
543
Intriguingly, since monocytes themselves express CXCR3 it is possible that CXCL9-10 production by 544 monocytes/macrophages leads to the recruitment of more monocytes in a positive feedback loop.
545
Previous studies have shown that CXCL9 and CXCL10 can be secreted by multiple cell types including 546 monocytes, endothelial cells, fibroblasts, inflammatory macrophages dendritic cells (particularly the cDC1 547 subtype) and tumor cells themselves (9, 12, 13, 66-68 ). In the context of cancer, previous data have 548 suggested that tumor cells (68), CD103 + DCs (9, 12) (69) or CD11b + cells (67) are major sources of CXCL9/10 within the tumor microenvironment. Notably, whilst we did observe that dual PD-1/CTLA-4 550 blockade enhanced CXCL9/10 production by CD103 + DCs and the bulk CD11b + population, our data 551 indicates that macrophages are the predominant source of CXCL9 and CXCL10 in the context of immune 552 checkpoint blockade both in mice and in patients. This was supported by single-cell RNA-seq in patient 553 datasets and alternative murine tumor models suggesting this is a pathway conserved in multiple tumor 554 types.
555
Our analysis of single cell RNA-seq data indicated that macrophages secreted higher levels of CXCL9-11 556 than dendritic cells in multiple cancer cell types. This was also observed in the context of immunotherapy 557 where the presence of CXCL10 or CXCL11 positive macrophages was a marker for benefit from 558 immunotherapy. Although CXCL9 was not prognostic within this patient cohort, we cannot exclude the 559 possibility that the low CXCL9 counts arose through technical limitation rather than a reduced expression 560 of CXCL9 relative to the other CXCR3 ligands CXCL10 and CXCL11. Our data suggest that the 561 production of CXCL9 and CXCL10 by the tumor cells themselves are dispensable for the therapeutic 562 effect of anti-PD-1 and anti-CTLA-4 and that knockout of these genes from tumor cells had minimal 563 impact on the overall concentration of these chemokines, particularly CXCL9, in the context of dual 564 combination therapy. However we cannot exclude a role for tumor-derived CXCL9/CXCL10 in tumors 565 with low immune infiltrate where their overall contribution to CXCL9/CXCL10 levels maybe more 566 pronounced. Interestingly our data also suggests a greater increase in CXCL10 mRNA, relative to CXCL9 567 mRNA, in CD45cells following combination therapy. Although this population includes tumor cells and 568 other host cells such as stroma, it would be interesting to confirm this at the protein level in future 569 experiments, particularly since we observed a significant decrease in CXCL10 protein levels within the 570 tumor microenvironment following CRISPR-Cas9 mediated deletion of CXCL10 from tumor cells. Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
28
Moreover, our data does not discount the importance of CXCL9/10 from other cell types including CD103 +
572
DCs which has previously been reported in the context of adoptive cellular therapy and immune checkpoint 573 blockade (12, 69). The production of CXCL9/10 by these cells can enhance T cell priming by facilitating 574 DC: T cell interactions and result in enhanced anti-tumor immunity. However, our data indicates a clear 575 role for CXCR3 dependent migration of T cells into tumors and that the predominant cellular source of 576 CXCL9/10 is macrophages. We believe one explanation for this apparent discrepancy is that whilst 577 macrophages are critical for CXCR3-dependent recruitment of T cells through their production of 578 CXCL9/10 in the tumor, CXCL9/10 production by other myeloid subsets, including CD103 + DCs is likely 579 to be important for T cell priming both within the tumor and in the draining lymph node. Therefore, whilst 580 our studies do not preclude an important role for CXCL9/10 production by DCs in promoting T cell 581 activation, they clearly indicate that macrophages are responsible for a significant proportion of these 582 chemokines. Notably, the requirement for immune cell trafficking into tumors following immune 583 checkpoint blockade is consistent with the emergence of new antigen specific immune cells at the tumor 584 site following therapy (70).
585
Although it was recently described that anti-TIM-3 therapy enhances CXCL9/10 production by CD103 +
586
DCs through direct modulation of TIM-3 expressed on CD103 + DCs (9), such a direct mechanism is 587 unlikely to contribute to the efficacy of PD-1 and CTLA-4 blockade, as PD-1 and CTLA-4 are not 588 expressed on either DCs or the tumoral macrophages in our study. Instead our data suggest that T cell 589 mediated increases in IFNγ and TNFα production are critical for this effect. Indeed, we observed that the 590 production of CXCL9 was dependent on IFNγ and TNFα, which is consistent with the role of STAT1 and 591 NFκB in enhancing the transcriptional activity of CXCL9 (71, 72) and with a previous report that indicated 592 that anti-PD-1 enhanced CXCL10 production from intratumoral CD11b + cells within tumors in an IFNγ 593 dependent manner in the context of adoptive cellular therapy (67). Transcriptome analysis of patient's 594 30 could potentially play a role in the spatial organisation and consequent activation of both CD8 + and CD4 + 618 T cells within the DLNs, as has been reported in the context of vaccination (78, 79) (41). Such interactions 619 have not been studied within the tumor microenvironment but this would be of significant interest given 620 our data suggest that the expression of CXCL9 by host immune cells is critical for the therapeutic effect 621 of immune checkpoint blockade.
622
In summary, our data indicate that the production of CXCR3 ligands is critical for the therapeutic effect 623 of dual anti-PD-1/anti-CTLA-4 therapy and identifies macrophages as the predominant source of CXCL9 624 both in preclinical models and in patients treated with immunotherapy. These cells were predicative of 625 response to immune checkpoint blockade and thus novel strategies to enhance CXCL9/10 production, 626 particularly by macrophages, have the potential to enhance the efficacy of immunotherapy in patients. x 10 5 MC38 cells (s.c.) and allowed to establish for 12 days (n = 6 mice per group) G) 1.5 x 10 5 E0771 cells (intra 831 mammary fat pad) and allowed to establish for 3 days (n = 5 -8 per group of representative experiment n=2) or H) 832 2 x 10 5 B16F10-OVA dim cells (s.c.) and allowed to establish for 4 days (n = 16-17 mice per group) before dual 833 treatment with anti-PD-1/anti-CTLA4 ± anti-CXCR3, as per B, except for MC38 which received only two doses of 834 combined therapy. 835 were dosed with either the S1PR1 inhibitor FTY720 (25 mg/kg) or DMSO control on days 13 and 14 post tumor 846 inoculation, and every two days subsequently. Data in right panel shows numbers of CD8 + and CD4 + T cells 847 collected from blood three days post initial FTY720 administration. Data is represented as the mean ± SEM of 6-7 848 mice per group (**** P<0.0001 *** P<0.001 ** P<0.01 1way, n.s. not significant, one-way ANOVA or two-way 849 ANOVA). 
